AMRX Q2 2023 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q2 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$599M+7.1% YoY

Gross Profit

$220M36.7% margin

Operating Income

$80M13.4% margin

Net Income

$12M2.0% margin

EPS (Diluted)

$0.08

QoQ Revenue Growth

+7.4%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$24M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$3.7B

Total Liabilities

$3.5B

Stockholders' Equity

$318M

Cash & Equivalents

$109M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$599M	$559M	+7.1%
Gross Profit	$220M	$201M	+9.7%
Operating Income	$80M	-$199M	+140.3%
Net Income	$12M	-$121M	+109.9%

Revenue Segments

Generics Segment

$374M62%

Av K A R E Segment

$128M21%

Amneal Specialty Pharma Segment

$97M16%